News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Over 20 Major Partners Join HopeLink`s Syndicated Network to Offer the HopeLink Clinical Trial Service (PR Newswire)...Lustgarten Foundation for Pancreatic Cancer Research National Brain Tumor Foundation; National Breast Cancer Coalition;...- May 14 7:02 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010514/hsm012.html

Posted on: 05/14/2001

"Yahoo - Over 20 Major Partners Join HopeLink's Syndicated Network to Offer the HopeLink Clinical Trial Service"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
^DJI
^IXIC
^SPC
^IIX
^PSE
10812.07
2070.89
1241.72
193.27
734.67
-9.24
-36.54
-3.95
-5.85
-14.18
delayed 20 mins - disclaimer

Monday May 14, 7:02 am Eastern Time

Press Release

SOURCE: HopeLink Corporation

Over 20 Major Partners Join HopeLink's Syndicated Network to Offer the HopeLink Clinical Trial Service

Partner Organizations Signed to Present HopeLink's Syndicated Network Include ALCASE, Cancer Research Foundation of America, Colorectal Cancer Network, Healthcommunities.com, International Myeloma Foundation, National Brain Tumor Foundation, National Multiple Sclerosis Society, National Prostate Cancer Coalition, Oncology Nursing Society, The Breast Cancer Fund, US TOO! and 0thers

MENLO PARK, Calif., May 14 /PRNewswire/ -- HopeLink Corporation today announced that more than 20 organizations including healthcare companies, non-profit organizations, patient advocacy groups, research cooperatives, and voluntary health societies have partnered with HopeLink to offer its groundbreaking clinical trial service to cancer patients and their advocates. HopeLink is building a syndicated network and Clinical Trial Service that are designed to improve the clinical trial development and enrollment processes. HopeLink's service has been available since December 2000 and currently lists oncology trials. The company expects to offer clinical trials in other disease states in the future.

"The quality, breadth and enthusiasm of our syndicated network partners endorses our approach to facilitating clinical trial awareness worldwide," said Jim Messemer, president and CEO, HopeLink. "When people are diagnosed with cancer, many turn to Internet search engines to quickly locate websites that have disease specific information. Our syndicated network is specifically designed to provide critical clinical trial information to the websites patients and their advocates are visiting most often." The more than 20 organizations that will be presenting HopeLink's Clinical Trial Service on their websites include: Alliance for Lung Cancer Advocacy, Support and Education (ALCASE); American Foundation for Urologic Disease; American-Italian Cancer Foundation; Annie Appleseed Project; Cancer Research Foundation of America; Cherubim Foundation; Colorectal Cancer Network; Florida Cancer Education Network; Healthcommunities.com's OncologyChannel.com; HealthFrontier.com; HealthLinks.net; International Myeloma Foundation; Kidney Cancer Association; Lung Cancer Online; Lustgarten Foundation for Pancreatic Cancer Research; National Brain Tumor Foundation; National Breast Cancer Coalition; National Multiple Sclerosis Society; National Prostate Cancer Coalition; Oncology Nursing Society; The Breast Cancer Fund; and US TOO! To view the live Clinical Trial Service on HopeLink's syndicated network, visit the following url: www.hopelink.com/about_service/find

The HopeLink Clinical Trial Service is a free, accessible and searchable directory of clinical trials that instantly provides patients, advocates, research professionals and healthcare organizations with the latest information on drug therapies under development, including enrollment information and eligibility requirements. HopeLink also offers its customers and partners a number of workflow, reporting and content management tools to facilitate clinical trial participation.

"HopeLink's service allows us to provide patients with easy access to clinical trials," said Rob Tufel, MSW, MPH, and director of patient services, National Brain Tumor Foundation. "Patients are now able to find all the information they need through our website without having to sort through the often overwhelming amount of information on the Internet."

"We are excited to incorporate HopeLink's services on OncologyChannel.com as it provides a much needed resource for patients and their families to instantly learn about the latest clinical trials," said Dr. Stanley J. Swierzewski III, founder and CEO, Healthcommunities.com. "Having as much information as possible about diagnosis and treatment options is very important to our audience. Our partnership with HopeLink helps us meet our goal of providing trustworthy medical information online."

"HopeLink's service has become one of the most used areas on our website," said Mike Katz, vice president, International Myeloma Foundation. "Useful and accurate information saves lives and HopeLink is helping us provide this information to myeloma patients around the world."

HopeLink does not recruit or enroll patients in clinical trials, accept advertising revenue, or collect per-patient compensation or "bounties." The company leverages its syndicated network of partner websites to help patients and their advocates self-select for clinical trials. HopeLink's customers include industry sponsors and investigative sites that pay service fees in exchange for enhanced clinical trial listings and process management tools.

"We believe that a self-referral model that empowers individuals will emerge as a major channel for patient enrollment in addition to the current flow from physician referrals," said Larry Hausner, vice president of strategic partnerships, HopeLink. "Our unique partnership strategy allows HopeLink to have enormous reach and touch millions of people seeking potentially lifesaving treatment options."

"We selected HopeLink as our partner because the company is patient-centered and has a policy not to accept per-patient bounties or resell patient lists to investigators," said Priscilla Savary, executive director, Colorectal Cancer Network. "HopeLink's service empowers our patients by allowing them to self-select for a clinical trial and is especially appealing because it allows us to offer this benefit with a minimal amount of effort on our part."

"HopeLink's search capabilities are easy-to-use, fast, and accurate," said Elizabeth G. Gomez, RN, MSN, AOCN, and editor of ONS Online, the official website of the Oncology Nursing Society. "We selected the HopeLink Clinical Trial Service because it enhanced our award-winning clinical trials content and we didn't have to spend precious resources to build it ourselves."

"The National Prostate Cancer Coalition is committed to ending the devastating impact prostate cancer has on American men and their families. To realize our mission, we must equip survivors and advocates across the country with the most useful and effective tools," said Skip Lockwood, director of programs and senior editor, National Prostate Cancer Coalition. "HopeLink's Clinical Trial Service is just what we have been looking for to help patients and families find potentially lifesaving treatments while advancing the research needed to find a cure for cancer."

"As a cancer advocacy group, one of the goals of the Cancer Research Foundation of America is to educate the public about the value of clinical trials and help individuals understand that trials are the only way to translate the amazing breakthroughs made in laboratories around the country to new, more effective treatments for patients," said Carolyn Aldige, President and Founder, Cancer Research Foundation of America. "Our partnership with HopeLink brings us one step closer to realizing this goal."

Organizations interested in presenting HopeLink's Clinical Trial Service on their websites and becoming a syndicated network partner can email info@hopelink.com. Clinical trial sponsors interested in listing trials on HopeLink's service may also email info@hopelink.com.

About the HopeLink Clinical Trial Service

The HopeLink Clinical Trial Service is a hosted, web-based application that facilitates patient enrollment and creates process efficiencies for organizations that sponsor and conduct clinical trials. This turnkey software solution, launched in December 2000, can be tailored to ensure successful deployment and integration of new and existing processes. The service is presented through a syndicated network of numerous partner websites.

About HopeLink

Headquartered in Menlo Park, CA, HopeLink is a privately held software company that provides products and services to improve the clinical trial development and enrollment processes. HopeLink's solutions aim to not only increase clinical trial awareness and exposure, but also to create efficiencies through standardization and automation of time-consuming processes. The company's investors and management team are comprised of experienced executives from the healthcare, high technology, and non-profit sectors. HopeLink can be reached at www.hopelink.com .

                     MAKE YOUR OPINION COUNT - Click Here
               http://tbutton.prnewswire.com/prn/11690X54625453

SOURCE: HopeLink Corporation

Email this story - Most-emailed articles - Most-viewed articles


Related News Categories: computers, health care, software

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740